Abstract:
:The potential uses of serological tests that detect HCV core antigens in biological fluids are highlighted. The most common serological tests utilized to detect exposure to HCV rely on the detection of antibodies to HCV. However, these tests cannot distinguish between individuals who have resolved their infection and those who remain actively infected with HCV. By contrast, the HCV core antigen test detects circulating HCV core antigen and identifies individuals who are actively infected with HCV. There is increasing interest in using the HCV core antigen test as a reflex test for seropositive individuals to identify individuals who are actively infected with HCV. In addition, the HCV core antigen test can be utilized to detect the early phase of HCV infection prior to the development of antibodies, both in the blood bank setting and in the diagnostic laboratory. Lastly, quantitative versions of the HCV core antigen test can be used to monitor the effectiveness of antiviral therapy.
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Dawson GJdoi
10.3851/IMP2463subject
Has Abstractpub_date
2012-01-01 00:00:00pages
1431-5issue
7 Pt Beissn
1359-6535issn
2040-2058journal_volume
17pub_type
杂志文章,评审abstract:BACKGROUND:Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy. METHODS:Serum HBV RNA ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2777
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor drug, could be a favourable drug for maintenance therapy in HIV-infected adolescents because it has few long-term side effects. However, data among adolescents switching from efavirenz (EFV) to RPV are limited. This study investigated the ph...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:10.3851/IMP3198
更新日期:2018-01-01 00:00:00
abstract::Infection with influenza viruses, including seasonal, avian and pandemic viruses, remains a worldwide public health problem. Although influenza virus infection is both vaccine preventable and drug treatable, high rates of mutation and reassortment of viruses can result in reduced effectiveness of vaccines or drugs. Cu...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2067
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also a...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:10.3851/IMP2938
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Rilpivirine-based regimens are now preferred or alternative first-line regimens according to many HIV treatment guidelines. Recently, a surveillance study conducted in Argentina determined that prevalence of pretreatment resistance to first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3147
更新日期:2017-01-01 00:00:00
abstract:BACKGROUND:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a charac...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND:Antiviral and immune-modulating properties of low-molecular-weight heparin (LMWH) against coronaviridae have been reported by in vitro studies, but no in vivo evidence is yet available. We sought to know whether the timing of prophylactic doses of LMWH during the course of COVID-19 may affect the time to SAR...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3377
更新日期:2021-01-18 00:00:00
abstract:BACKGROUND:The tuberculosis (TB) mortality rate of registered TB patients in Malawi is 23%, and 59% of the deaths occur in the first 2 months of treatment. HIV-related complications appear to be an important cause. Starting antiretroviral therapy early during tuberculosis treatment may improve outcome but problems ofte...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). This study aimed to determine the influence of the favourable IL28B genotype on early viral kinetics during therapy with TVR/PR in HIV-HCV-coinf...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:10.3851/IMP2921
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:10.3851/IMP2972
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究,随机对照试验
doi:
更新日期:2008-01-01 00:00:00
abstract::Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determi...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2000-09-01 00:00:00
abstract:BACKGROUND:Serum HBV DNA level is crucial in the management of chronic hepatitis B (CHB); however, the assay is expensive and cannot be used widely. Therefore, we explored the possibility of hepatitis B surface antigen (HBsAg) quantification as a surrogate marker for HBV DNA level in CHB patients. METHODS:A total of 2...
journal_title:Antiviral therapy
pub_type: 杂志文章,随机对照试验
doi:10.3851/IMP1696
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:Transmitted drug resistance (TDR) limits antiretroviral options and thus complicates the management of HIV-positive patients. HIV disproportionately affects the southern US, but available national estimates of TDR prevalence principally reflect large metropolitan centres outside this region. METHODS:The Duk...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2009-01-01 00:00:00
abstract::HBV is a hepatotropic and non-cytopathic virus that causes more than one million deaths annually from liver cirrhosis and hepatocellular carcinoma. As the virus itself is non-cytopathic, it is widely accepted that both viral control and liver pathology are mediated by the host immune system. Until recently, the focus ...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP1620
更新日期:2010-01-01 00:00:00
abstract:OBJECTIVE:To assess the impact of nucleoside analogue reverse transcriptase inhibitor (NRTI) combination therapy on muscle and liver lactate metabolism in HIV-infected patients. METHODS:This cross-sectional study involved HIV-infected patients who were either antiretroviral-naive (Group 1) or were receiving either a s...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:
更新日期:2005-01-01 00:00:00
abstract::Active pharmaceutical ingredients (APIs) are the molecular entities that exert the therapeutic effects of medicines. This article provides an overview of the major APIs that are entered into antiretroviral therapy (ART), outlines how APIs are manufactured, and examines the regulatory and cost frameworks of manufacturi...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2897
更新日期:2014-01-01 00:00:00
abstract::HIV drug resistance testing is becoming an integral part of antiretroviral drug development and of patient management. The parameters that characterize the performance of both phenotypic and genotypic assays and the validation of this performance are essential to their proper use for these applications. Several princi...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:2000-03-01 00:00:00
abstract::Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3362
更新日期:2020-06-04 00:00:00
abstract::Zalcitabine (ddC) is a nucleoside analogue reverse transcriptase inhibitor with demonstrated clinical benefit in combination use. More widespread use of zalcitabine has been limited by a number of factors including peripheral neuropathy and three times daily dosing. However, screening for the risk factors for peripher...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:1998-01-01 00:00:00
abstract:BACKGROUND:US guidelines recommend genotyping for persons newly diagnosed with HIV infection to identify transmitted drug resistance mutations associated with decreased susceptibility to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. To date, testin...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2780
更新日期:2015-01-01 00:00:00
abstract::Cytomegalovirus (CMV) remains a leading cause of morbidity after solid organ transplantation. The efficiency of antivirals for the treatment of CMV infections may be hampered because of the emergence of CMV resistance to antivirals. The development of CMV multidrug resistance, which remains uncommon but does occur, co...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2818
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:HBV antiviral therapy has the potential to reduce the burden of HBV-related liver disease by suppressing HBV DNA replication to undetectable levels, reducing the progression of liver fibrosis and reducing the risk of hepatocellular carcinoma (HCC) development. Treatment outcomes and long-term benefits requir...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:10.3851/IMP3219
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations. METHODS:We used data from a national study to compare different treatment pathways during pregnancy. Overall, 321...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2008-01-01 00:00:00
abstract::HIV drug resistance remains one of the most important influences on long-term therapeutic prospects. Resistance and therapeutic failure arises out of the selection and preservation of randomly generated genomic mutations that confer a replicative advantage in the presence of one or more antiretrovirals. The primary co...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:2001-01-01 00:00:00
abstract::Ribavirin is a guanosine analogue that has little antiviral activity when used alone, but considerably enhances the efficacy of conventional and pegylated interferon in the treatment of hepatitis C virus (HCV). The precise mode of action of ribavirin is not fully understood; however, it is crucial for the achievement ...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND:Endothelial progenitor cells (EPCs) are involved in the endothelium repair. Low circulating EPC levels are predictive of cardiovascular events in HIV-negative subjects. The impact of HIV infection on EPCs, and the role of EPCs in HIV-associated cardiovascular disease, is not known. We hypothesized that circu...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2013
更新日期:2012-01-01 00:00:00
abstract::Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2425
更新日期:2012-01-01 00:00:00
abstract::HCV-related liver disease is an important contributor to morbidity and mortality in the HIV-infected population. Successful treatment of HIV-HCV-coinfected patients is followed by favourable clinical outcomes. While the combination of pegylated interferon and ribavirin remains the mainstay in the treatment of non-1 HC...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2601
更新日期:2013-01-01 00:00:00